These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37545290)

  • 41. Radical consolidative treatment provides a clinical benefit and long-term survival in patients with synchronous oligometastatic non-small cell lung cancer: A phase II study.
    Arrieta O; Barrón F; Maldonado F; Cabrera L; Corona-Cruz JF; Blake M; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; García O; Arén O; De la Garza J
    Lung Cancer; 2019 Apr; 130():67-75. PubMed ID: 30885354
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical option of pemetrexed-based versus paclitaxel-based first-line chemotherapeutic regimens in combination with bevacizumab for advanced non-squamous non-small-cell lung cancer and optimal maintenance therapy: evidence from a meta-analysis of randomized control trials.
    Huang LT; Cao R; Wang YR; Sun L; Zhang XY; Guo YJ; Zhao JZ; Zhang SL; Jing W; Song J; Han CB; Ma J
    BMC Cancer; 2021 Apr; 21(1):426. PubMed ID: 33865364
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
    Xu TP; Shen H; Liu LX; Shu YQ
    Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chemotherapy for advanced non-small cell lung cancer in the elderly population.
    Santos FN; de Castria TB; Cruz MR; Riera R
    Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD010463. PubMed ID: 26482542
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients.
    Dal Bello MG; Filiberti RA; Alama A; Orengo AM; Mussap M; Coco S; Vanni I; Boccardo S; Rijavec E; Genova C; Biello F; Barletta G; Rossi G; Tagliamento M; Maggioni C; Grossi F
    J Transl Med; 2019 Mar; 17(1):74. PubMed ID: 30849967
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC-A retrospective cohort study.
    Lang D; Horner A; Brehm E; Akbari K; Hergan B; Langer K; Asel C; Scala M; Kaiser B; Lamprecht B
    Lung Cancer; 2019 Aug; 134():59-65. PubMed ID: 31319996
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO).
    Vansteenkiste J; Barlesi F; Waller CF; Bennouna J; Gridelli C; Goekkurt E; Verhoeven D; Szczesna A; Feurer M; Milanowski J; Germonpre P; Lena H; Atanackovic D; Krzakowski M; Hicking C; Straub J; Picard M; Schuette W; O'Byrne K
    Ann Oncol; 2015 Aug; 26(8):1734-40. PubMed ID: 25939894
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
    West H; McCleod M; Hussein M; Morabito A; Rittmeyer A; Conter HJ; Kopp HG; Daniel D; McCune S; Mekhail T; Zer A; Reinmuth N; Sadiq A; Sandler A; Lin W; Ochi Lohmann T; Archer V; Wang L; Kowanetz M; Cappuzzo F
    Lancet Oncol; 2019 Jul; 20(7):924-937. PubMed ID: 31122901
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): systematic review and meta-analysis.
    Botrel TE; Clark O; Clark L; Paladini L; Faleiros E; Pegoretti B
    Lung Cancer; 2011 Oct; 74(1):89-97. PubMed ID: 21377753
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer.
    Liu SV; Camidge DR; Gettinger SN; Giaccone G; Heist RS; Hodi FS; Ready NE; Zhang W; Wallin J; Funke R; Waterkamp D; Foster P; Iizuka K; Powderly J
    Eur J Cancer; 2018 Sep; 101():114-122. PubMed ID: 30053670
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
    Rizvi NA; Cho BC; Reinmuth N; Lee KH; Luft A; Ahn MJ; van den Heuvel MM; Cobo M; Vicente D; Smolin A; Moiseyenko V; Antonia SJ; Le Moulec S; Robinet G; Natale R; Schneider J; Shepherd FA; Geater SL; Garon EB; Kim ES; Goldberg SB; Nakagawa K; Raja R; Higgs BW; Boothman AM; Zhao L; Scheuring U; Stockman PK; Chand VK; Peters S;
    JAMA Oncol; 2020 May; 6(5):661-674. PubMed ID: 32271377
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
    Iyengar P; Wardak Z; Gerber DE; Tumati V; Ahn C; Hughes RS; Dowell JE; Cheedella N; Nedzi L; Westover KD; Pulipparacharuvil S; Choy H; Timmerman RD
    JAMA Oncol; 2018 Jan; 4(1):e173501. PubMed ID: 28973074
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Predictive and Prognostic Value of CYFRA 21-1 for Advanced Non-small Cell Lung Cancer Treated with EGFR-TKIs.
    Takeuchi A; Oguri T; Sone K; Ito K; Kitamura Y; Inoue Y; Asano T; Fukuda S; Kanemitsu Y; Takakuwa O; Ohkubo H; Takemura M; Maeno K; Ito Y; Niimi A
    Anticancer Res; 2017 Oct; 37(10):5771-5776. PubMed ID: 28982900
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chemotherapy for advanced non-small cell lung cancer in the elderly population.
    Santos FN; Castria TB; Cruz MR; Riera R
    Sao Paulo Med J; 2016; 134(5):465-466. PubMed ID: 27901246
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer.
    Ciuleanu T; Tsai CM; Tsao CJ; Milanowski J; Amoroso D; Heo DS; Groen HJ; Szczesna A; Chung CY; Chao TY; Middleton G; Zeaiter A; Klingelschmitt G; Klughammer B; Thatcher N
    Lung Cancer; 2013 Nov; 82(2):276-81. PubMed ID: 23992877
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Atezolizumab First-Line Combination Therapy: A Review in Metastatic Nonsquamous NSCLC.
    Dhillon S; Syed YY
    Target Oncol; 2019 Dec; 14(6):759-768. PubMed ID: 31728860
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.
    Herbst RS; Redman MW; Kim ES; Semrad TJ; Bazhenova L; Masters G; Oettel K; Guaglianone P; Reynolds C; Karnad A; Arnold SM; Varella-Garcia M; Moon J; Mack PC; Blanke CD; Hirsch FR; Kelly K; Gandara DR
    Lancet Oncol; 2018 Jan; 19(1):101-114. PubMed ID: 29169877
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cytokeratin-19 fragments, nucleosomes and neuron-specific enolase as early measures of chemotherapy response in non-small cell lung cancer.
    Alm El-Din MA; Farouk G; Nagy H; Abd Elzaher A; Abo El-Magd GH
    Int J Biol Markers; 2012 Jul; 27(2):e139-46. PubMed ID: 22467097
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib.
    Chen F; Luo X; Zhang J; Lu Y; Luo R
    Med Oncol; 2010 Sep; 27(3):950-7. PubMed ID: 19830603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.